Company Coverage
Sino Biopharmaceutical (1177 HK): 1H26: Results In Line; Innovative Products Continue To Drive Growth
BUY (Maintained)
Current price:
Target price:
Upside:
HK$4.79
HK$7.20
+50.31%
Analyst
Analyst
Highlights
Sino Biopharm reported satisfactory 1H26 results, with revenue up 10.6% yoy to Rmb19.44b; underlying net profit was Rmb3.34b, up 8.1% yoy, or 92.3% yoy if excluding the Sinovac LS dividend received in 1H25.
Embracing AI, the company has achieved breakthroughs in its AI-driven drug discovery and significantly enhanced operating efficiency. Maintaining its double-digit 2026 revenue growth target, it expects innovative drugs sales and out-licensing income to further boost earnings in 2026.
Maintain BUY and target price of HK$7.20.
Analysis
1H26 results satisfactory. Sino Biopharmaceutical (Sino Biopharm, or SBP Group) reported 1H26 revenue of Rmb19.44b, up 10.6% yoy, of which Rmb975m came from out-licensing (1H25: Rmb44m). Adjusted net profit rose 8.1% yoy to Rmb3.34b, or 92.3% yoy if excluding the Sinovac LS dividend received in 1H25. The interim dividend was raised 40% yoy to 7 HK cents per share.
Highlights
Sino Biopharm reported satisfactory 1H26 results, with revenue up 10.6% yoy to Rmb19.44b; underlying net profit was Rmb3.34b, up 8.1% yoy, or 92.3% yoy if excluding the Sinovac LS dividend received in 1H25.
Embracing AI, the company has achieved breakthroughs in its AI-driven drug discovery and significantly enhanced operating efficiency. Maintaining its double-digit 2026 revenue growth target, it expects innovative drugs sales and out-licensing income to further boost earnings in 2026.
Maintain BUY and target price of HK$7.20.
Analysis
1H26 results satisfactory. Sino Biopharmaceutical (Sino Biopharm, or SBP Group) reported 1H26 revenue of Rmb19.44b, up 10.6% yoy, of which Rmb975m came from out-licensing (1H25: Rmb44m). Adjusted net profit rose 8.1% yoy to Rmb3.34b, or 92.3% yoy if excluding the Sinovac LS dividend received in 1H25. The interim dividend was raised 40% yoy to 7 HK cents per share.
BUY (Maintained)
Current price:
Target price:
Upside:
HK$4.79
HK$7.20
+50.31%
Analyst
Analyst
IMPORTANT NOTICE - DISCLOSURES AND DISCLAIMERS
This report is provided subject to, and must be read together with, the full Disclosures / Disclaimers available at this link, which are incorporated by reference into this report. In particular, this report is intended for general circulation and informational purposes only and does not constitute personal investment advice or a recommendation to buy or sell any investment product or security. You should independently evaluate the information and, where necessary, seek advice from a qualified financial adviser regarding the suitability of any investment. Analyst certifications required under applicable regulations, including SEC Regulation AC (where relevant), are included in this report. By accessing, receiving or using this report, you acknowledge that you have read, understood and agreed to be bound by the Disclosures / Disclaimers, as may be amended, supplemented or updated from time to time.
Related articles
17 Sept 2026
Trip.com (9961 HK) - 2Q26: In-line Results; 3Q26 Growth To Slow On Regulatory Pressure; Expect A Recovery In 2027
1 Sept 2026
China Resources Land (1109 HK): 1H26: In Line; Mall Operations Remain The Key Outperformer
2 Sept 2026
Pateo Connect Technology (2889 HK): 1H26: Core Results In Line, But GAAP Bottom-line Pressured By Share-based Compensation
Our latest research
2 Oct 2026
TA: CSPC Pharmaceutical Group (1093 HK) / China Resources Power Holdings (0836 HK)
2 Oct 2026
New World Development (17 HK): FY26: Core Profit Turns Positive; 11 SKIES Exit Helps Long-term Cash Flow, But Debt Metrics Warrant Caution
30 Sept 2026